Protect Clinical Assets. Preserve Enterprise Value.
ClinPro Trials™ today announced the availability of its Independent Executive Compliance Intelligence™ service for investors seeking objective visibility into clinical trial compliance, inspection readiness and regulatory exposure across their clinical investment portfolios. As The Compliance CRO™, ClinPro Trials provides independent executive assessments designed to help protect clinical assets and preserve enterprise value.
Every investor expects scientific risk.
Few expect compliance failure.
Fewer expect to discover it after years of investment and hundreds of millions of dollars—during a pre-approval inspection.
A pre-approval inspection often reveals compliance deficiencies that could have been identified much earlier.
Not because the science failed.
But because compliance drifted during trial execution.
Every milestone appeared to have been achieved.
Every executive update suggested progress.
But one critical question remained unanswered:
Do we truly understand the compliance risk, inspection readiness and regulatory exposure of the clinical asset we are funding?
ClinPro Trials™ was established to answer that question.
As The Compliance CRO™, ClinPro Trials provides Independent Executive Compliance Intelligence™ that gives investors objective visibility into compliance risk, execution drift, inspection readiness and regulatory exposure across their clinical investment portfolio—before compliance risks become enterprise value risks.
Independent. Objective. Governance-Focused.
Independent executive decisions require independent executive intelligence.
Following the Independent Executive Compliance Assessment, ClinPro Trials works with investors to remediate compliance issues and recommend an appropriate level of ongoing independent executive oversight based on the development stage, complexity and compliance risk of each clinical asset.
Drawing on more than 30 years of global regulatory and inspection-readiness experience, ClinPro Trials has prepared for, managed and remediated inspections involving the FDA, MHRA, EMA, PMDA and TGA.
Because protecting clinical assets begins with understanding their true state of compliance and inspection readiness.
Protect Clinical Assets. Preserve Enterprise Value.
To learn more or request a Portfolio Compliance Assessment, visit https://clinprotrials.com or email info@clinprotrials.com.